- Home
- ZNTL vs NPCT Comparison
ZNTL vs NPCT Comparison
Compare ZNTL & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- NPCT
- Stock Information
- Founded
- ZNTL 2014
- NPCT 2020
- Country
- ZNTL United States
- NPCT United States
- Employees
- ZNTL N/A
- NPCT N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- NPCT Investment Managers
- Sector
- ZNTL Health Care
- NPCT Finance
- Exchange
- ZNTL Nasdaq
- NPCT Nasdaq
- Market Cap
- ZNTL 238.2M
- NPCT 340.7M
- IPO Year
- ZNTL 2020
- NPCT N/A
- Fundamental
- Price
- ZNTL $3.12
- NPCT $11.34
- Analyst Decision
- ZNTL Buy
- NPCT
- Analyst Count
- ZNTL 7
- NPCT 0
- Target Price
- ZNTL $10.86
- NPCT N/A
- AVG Volume (30 Days)
- ZNTL 1.2M
- NPCT 107.1K
- Earning Date
- ZNTL 11-04-2024
- NPCT 01-01-0001
- Dividend Yield
- ZNTL N/A
- NPCT 9.82%
- EPS Growth
- ZNTL N/A
- NPCT N/A
- EPS
- ZNTL N/A
- NPCT N/A
- Revenue
- ZNTL $40,560,000.00
- NPCT N/A
- Revenue This Year
- ZNTL N/A
- NPCT N/A
- Revenue Next Year
- ZNTL N/A
- NPCT N/A
- P/E Ratio
- ZNTL N/A
- NPCT N/A
- Revenue Growth
- ZNTL N/A
- NPCT N/A
- 52 Week Low
- ZNTL $2.83
- NPCT $8.58
- 52 Week High
- ZNTL $18.24
- NPCT $10.63
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- NPCT 31.22
- Support Level
- ZNTL $2.92
- NPCT $11.46
- Resistance Level
- ZNTL $3.23
- NPCT $11.55
- Average True Range (ATR)
- ZNTL 0.17
- NPCT 0.15
- MACD
- ZNTL 0.00
- NPCT -0.05
- Stochastic Oscillator
- ZNTL 38.33
- NPCT 9.68
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.